Crespin, D. J., Federspiel, J., Biddle, A. K., Jonas, D., Stearns, S. C., & Rossi, J. S. (n.d.). Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome. Presented at the International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting.

Crespin, D. J., Jeff Federspiel, A. K. Biddle, D. Jonas, S. C. Stearns, and J. S. Rossi. “Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome.,” n.d.

Crespin DJ, Federspiel J, Biddle AK, Jonas D, Stearns SC, Rossi JS. Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome. In.

Crespin, D. J., et al. Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome.

Crespin DJ, Federspiel J, Biddle AK, Jonas D, Stearns SC, Rossi JS. Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome.